These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 17471972)

  • 21. Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell-penetrating peptide.
    Wei B; Wei Y; Zhang K; Wang J; Xu R; Zhan S; Lin G; Wang W; Liu M; Wang L; Zhang R; Li J
    Biomed Pharmacother; 2009 May; 63(4):313-8. PubMed ID: 18823738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a transferrin receptor-targeting HVJ-E vector.
    Shimbo T; Kawachi M; Saga K; Fujita H; Yamazaki T; Tamai K; Kaneda Y
    Biochem Biophys Res Commun; 2007 Dec; 364(3):423-8. PubMed ID: 17961511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engineering genomics. RNA antagonists--a new class of antisense drugs.
    Orum H
    IEEE Eng Med Biol Mag; 2005; 24(4):81-7. PubMed ID: 16119218
    [No Abstract]   [Full Text] [Related]  

  • 24. Eric S. Lander.
    Lander ES
    Nat Rev Drug Discov; 2004 Sep; 3(9):730. PubMed ID: 15368656
    [No Abstract]   [Full Text] [Related]  

  • 25. Adenovirus-mediated expression of cyclooxygenase-2 antisense reverse abnormal genetic profile of human adhesion fibroblasts.
    Saed GM; Al-Hendy A; Salama SA; Diamond MP
    Fertil Steril; 2008 May; 89(5 Suppl):1455-60. PubMed ID: 17624339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The RNA revolution].
    Scoazec JY
    Ann Pathol; 2006 Sep; 26(4):275-80. PubMed ID: 17128155
    [No Abstract]   [Full Text] [Related]  

  • 27. Controlled delivery of antisense oligonucleotides: a brief review of current strategies.
    Zhao X; Pan F; Holt CM; Lewis AL; Lu JR
    Expert Opin Drug Deliv; 2009 Jul; 6(7):673-86. PubMed ID: 19552611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A
    Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delivery of intercellular adhesion molecule-1 antisense oligonucleotides using a topical hydrogel tissue sealant in a murine partial nephrectomy/ischemia model.
    Phull H; Lien YH; Salkini MW; Escobar C; Lai LW; Ramakumar S
    Urology; 2008 Sep; 72(3):690-5. PubMed ID: 18336877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors determining the efficacy of nuclear delivery of antisense oligonucleotides by gold nanoparticles.
    Liu Y; Franzen S
    Bioconjug Chem; 2008 May; 19(5):1009-16. PubMed ID: 18393455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RNA interference as an anticancer therapy: a patent perspective.
    Dykxhoorn DM
    Expert Opin Ther Pat; 2009 Apr; 19(4):475-91. PubMed ID: 19441927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted pre-mRNA modification for gene silencing and regulation.
    Zhao X; Yu YT
    Nat Methods; 2008 Jan; 5(1):95-100. PubMed ID: 18066073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RNA interference targeting the ACE gene reduced blood pressure and improved myocardial remodelling in SHRs.
    He J; Bian Y; Gao F; Li M; Qiu L; Wu W; Zhou H; Liu G; Xiao C
    Clin Sci (Lond); 2009 Feb; 116(3):249-55. PubMed ID: 18605985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cationic lipids and polymers mediated vectors for delivery of siRNA.
    Zhang S; Zhao B; Jiang H; Wang B; Ma B
    J Control Release; 2007 Oct; 123(1):1-10. PubMed ID: 17716771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug discovery approaches targeting the PI3K/Akt pathway in cancer.
    Garcia-Echeverria C; Sellers WR
    Oncogene; 2008 Sep; 27(41):5511-26. PubMed ID: 18794885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Achieving targeted and quantifiable alteration of mRNA splicing with Morpholino oligos.
    Morcos PA
    Biochem Biophys Res Commun; 2007 Jun; 358(2):521-7. PubMed ID: 17493584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From gene replacement to gene manipulation.
    Baxter P
    Dev Med Child Neurol; 2007 Aug; 49(8):563. PubMed ID: 17635195
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeting RNA: an emerging hope for treating muscular dystrophy.
    Extance A
    Nat Rev Drug Discov; 2009 Dec; 8(12):917-8. PubMed ID: 19949390
    [No Abstract]   [Full Text] [Related]  

  • 39. Correlation between gene silencing activity and structural features of antisense oligodeoxynucleotides and target RNA.
    Liao L; Li Z
    In Silico Biol; 2007; 7(4-5):527-34. PubMed ID: 18391241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug development of MET inhibitors: targeting oncogene addiction and expedience.
    Comoglio PM; Giordano S; Trusolino L
    Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.